West Pharmaceutical Services (WST) Stock
Key components supplier for injectable drug delivery. Here's the price, business snapshot, and what's worth knowing about West Pharmaceutical Services in June 2026.
West Pharmaceutical Services Inc (WST) supplies components and delivery systems for injectable drugs and vaccines, including stoppers, seals, syringe components and containment technologies. Its customers are pharmaceutical and biotechnology companies that rely on high-quality, regulatory-compliant components for sterile drug packaging and drug delivery. West benefits from long-term trends such as growth in biologic medicines, injectable therapeutics and outsourcing of containment and delivery manufacturing, supporting steady demand for precision components. Investors should note the company operates in a manufacturing- and technology-intensive niche where quality, regulatory approval and supply-chain resilience are key competitive advantages. Financially, West is a mid-cap company (market cap approx. $20.1bn) with a history of generating operating cash flow, though revenues can be influenced by customers' development cycles and contract timing. Key risks include regulatory scrutiny, competition, raw-material and manufacturing disruptions, and customer concentration. This summary is educational only and not personalised investment advice; perform your own due diligence.
Why It’s Moving
WST Shares Climb on Momentum from Prior Earnings Beat and GLP-1 Demand Surge
- Q3 EPS of $1.96 crushed estimates by $0.29, with revenue up 7.7% YoY to $804.6M, underscoring resilient organic growth and margin resilience.
- Management lifted FY2025 EPS outlook to $7.06-$7.11 and revenue toward $3.1B, signaling confidence in sustained demand for specialized drug delivery systems.
- KeyCorp analysts upgraded their target and rating, spotlighting GLP-1 tailwinds and high-volume packaging expansions as pivotal upside drivers.
WST Shares Climb on Momentum from Prior Earnings Beat and GLP-1 Demand Surge
- Q3 EPS of $1.96 crushed estimates by $0.29, with revenue up 7.7% YoY to $804.6M, underscoring resilient organic growth and margin resilience.
- Management lifted FY2025 EPS outlook to $7.06-$7.11 and revenue toward $3.1B, signaling confidence in sustained demand for specialized drug delivery systems.
- KeyCorp analysts upgraded their target and rating, spotlighting GLP-1 tailwinds and high-volume packaging expansions as pivotal upside drivers.
When is the next earnings date for WEST PHARMACEUTICAL SERVICES INC (WST)?
West Pharmaceutical Services (WST) has its next earnings call scheduled for April 23, 2026, covering results for Q1 2026. This follows the pattern of late April releases observed in prior quarters, with the most recent report on February 12, 2026, addressing Q4 2025. Investors should monitor for official confirmation, as estimates align across multiple historical data points.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying West Pharmaceutical Services' stock, anticipating a potential price increase.
Financial Health
West Pharmaceutical is performing well financially, showing strong revenue and cash flow generation.
Dividend
West Pharmaceutical's low dividend yield of 0.27% suggests limited returns from dividends. If you invested $1000, you would be paid $2.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring WST
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Manufacturing: What's Next for U.S. Reshoring?
Eli Lilly is investing $3.5 billion in a new U.S. plant to boost production of its popular obesity drugs. This move signals a broader trend of pharmaceutical reshoring, creating opportunities for companies that support and build out the domestic life sciences manufacturing infrastructure.
Published: 2 February 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketGlobal Pharma Titans | Brazil Healthcare Investment
Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.
Published: 16 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Demand from biologics
Biologic and injectable drug growth supports long-term demand for precision components, though revenue timing can vary with customers' development cycles.
Quality and execution
Manufacturing excellence and regulatory compliance are competitive advantages, but execution and supply‑chain disruptions can materially affect results.
Exposure to pharma
West offers indirect exposure to global pharmaceutical and biotech activity, balanced by risks such as customer concentration and regulatory scrutiny.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
